Anecortave Acetate: A New Approach for the Medical Treatment of Glaucoma

Hennessy, Amy; Robin, Alan L.

doi:10.1007/978-0-387-76700-0_89

Cited by 2 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its angiostatic properties originally were being investigated for wet age-related macular degeneration (AMD), but observations of IOP lowering effect led to glaucoma clinical investigations. Chemical modifications to eliminate the glucocorticoid activity and its mechanism of action were thought to enhance outflow at the trabecular meshwork [55,56]. The hydrophobic molecule resisted diffusion and could therefore create a sustained release depot when injected in the juxtascleral or sub-tenons space.…”

Section: Delivery Devices In Clinical Developmentmentioning

confidence: 99%

Ocular Drug Delivery for Glaucoma Management

et al. 2012

View full text Add to dashboard Cite

Current glaucoma management modalities are hindered by low patient compliance and adherence. This can be due to highly complex treatment strategies or poor patient understanding. Treatments focus on the management or reduction of intraocular pressure. This is most commonly done through the use of daily topical eye drops. Unfortunately, despite effective therapies, glaucoma continues to progress, possibly due to patients not adhering to their treatments. In order to mitigate these patient compliance issues, many sustained release treatments are being researched and are entering the clinic. Conjunctival, subconjunctival, and intravitreal inserts, punctal plugs, and drug depots are currently in clinical development. Each delivery system has hurdles, yet shows promise and could potentially mitigate the current problems associated with poor patient compliance.

show abstract

Section: Delivery Devices In Clinical Developmentmentioning

confidence: 99%

Ocular Drug Delivery for Glaucoma Management

et al. 2012

View full text Add to dashboard Cite

show abstract

The role of transforming growth factor β in glaucoma and the therapeutic implications

et al. 2013

View full text Add to dashboard Cite

Glaucoma is a progressive optic neuropathy frequently associated with elevated intraocular pressure, ocular vascular changes and extracellular matrix remodelling at the optic nerve head and in the trabecular meshwork. The pathogenesis is multifactorial and complex, but many recent studies have suggested that transforming growth factor-β (TGF-β) plays a major role in the process. Significantly elevated levels of TGF-β have been identified in the anterior chamber of glaucomatous eyes. TGF-β has also been shown to directly cause increased intraocular pressure. It is believed that this occurs through complex interaction with the trabecular meshwork, leading to decreased aqueous humour outflow. These processes occur through specific interactions with various proteins and signalling molecules also present in ocular tissues. By understanding the role that TGF-β plays in the pathogenesis of glaucoma, alternative therapeutic agents can be developed, which target these pathways and improve and assist in the management of disease. This review will cover previous investigative studies and discuss the current understanding of TGF-β's role in glaucoma and how it may serve as a potential therapeutic target.

show abstract

Anecortave Acetate: A New Approach for the Medical Treatment of Glaucoma

Cited by 2 publications

References 39 publications

Ocular Drug Delivery for Glaucoma Management

Ocular Drug Delivery for Glaucoma Management

The role of transforming growth factor β in glaucoma and the therapeutic implications

Contact Info

Product

Resources

About